The Saudi Food and Drug Authority (SFDA) and King Abdulaziz University (KAU) signed a Memorandum of Understanding (MoU) today to enhance joint capabilities between the two sides. The MoU was signed on the sidelines of the Global Health Exhibition 2024 in Riyadh, which will be held from October 21 to 23, 2024.

The Chief Executive Officer of the SFDA, H.E. Dr. Hisham S. Aljadhey, signed the MoU alongside the President of KAU, Dr. Tareef Alaama.

The MoU aims to establish a comprehensive framework for cooperation in providing rehabilitation, training, consulting services, studies, and research, as well as facilitating the exchange of expertise, data, and statistics related to their activities.

The cooperation will support and develop innovation in medical devices and modern technologies. Additionally, it will involve the use of artificial intelligence (AI) for evaluating pharmaceutical preparations.

Key areas of collaboration include designating KAU laboratories as reference laboratories in specific fields; creating educational courses and programs focused on the legislation and regulations of medical devices and AI; submitting and publishing scientific materials and lectures; and facilitating the participation of both sides in exhibitions, conferences, and workshops organized in their shared fields.

The partnership between SFDA and KAU represents a significant step forward in advancing medical technology and improving healthcare outcomes in the Kingdom of Saudi Arabia. By combining their expertise and resources, this collaboration will contribute to a healthier and more prosperous future for the Kingdom.